OLX 301A
Alternative Names: OLX-10212; OLX-301A; OLX301A NLatest Information Update: 01 Dec 2023
Price :
$50 *
At a glance
- Originator OliX Pharmaceuticals
- Class Eye disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dry age-related macular degeneration; Wet age-related macular degeneration
Most Recent Events
- 29 Nov 2023 Adverse events data from the phase I study in Wet age-related macular degeneration and Dry age-related macular degeneration were released by OliX Pharmaceuticals (Ophthalmic)
- 03 Aug 2022 US FDA approves IND application for OLX 301A in Age-related macular degeneration in August 2022
- 04 Jul 2022 OliX Pharmaceuticals submits IND to the US FDA in Age-related macular degeneration